Efficacy, patterns of relapse and safety of adjuvant treatment with intraperitoneal (i.p.) yttrium-90-labeled HMFG1 monoclonal antibody (R1549) in epithelial ovarian cancer (EOC)

LFAG Massuger, A. Lopes, AA Epenetos, M.V. Seiden, BB Benigno, JT Soper, J. Markowska, R Vyzula, RHM Verheijen, T Jobling

Research output: Contribution to conferenceAbstractOther research output

Original languageEnglish
Publication statusPublished - 2004
EventIGCS - Edinburgh, Ireland
Duration: 3 Oct 20048 Oct 2016

Conference

ConferenceIGCS
Country/TerritoryIreland
CityEdinburgh
Period3/10/048/10/16

Cite this